CEO: Michael Gilman

Advent Contact: Raj Parekh

First-in-class small molecule modulators of RNA

Arrakis is building a proprietary platform to enable the rational, structure-based design of orally acting small molecules that bind RNA, and so directly modulate RNA function.

Advent founded Arrakis in 2014.

Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform